TriLink BioTechnologies社 February TriLink Messenger

Research News

Rare Disease Day - Six mRNA Therapeutics in Development

Even though each disease is rare in and of itself, patients with rare diseases are common, accounting for 4%–6% of the worldwide population or 260–450 million persons.
This blog post highlights progress made on mRNA-based protein replacement treatments for six rare diseases.

Identifying an epicardial cell subset that drives cardiac repair

Continued innovation promises new and improved mRNA-based therapeutics

Researchers at Weill Cornell Medical College and the Icahn School of Medicine at Mount Sinai used TriLink’s CleanCap® technology to identify an epicardial progenitor cell subpopulation that drives heart repair and regeneration in zebrafish.

TriLink’s CleanCap® technology featured in a recent Nature Medicine review of mRNA nanomedicine, which highlights the importance of co-transcriptional capping to reduce unwanted immunostimulation and increase translation efficiencies.

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。